NEWS RELEASE – First-Quarter Revenue of $1.01 Billion – – Updates 2024 Guidance – The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, organic revenue decreased 3.3%. On a segment basis, both the Manufacturing and Research Models and Services (RMS) business segments reported organic revenue gr ...

Wall Street analysts expect Charles River Laboratories (CRL) to post quarterly earnings of $2.05 per share in its upcoming report, which indicates a year-over-year decline of 26.3%. Revenues are expected to be $997.24 million, down 3.1% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, i ...

Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks w ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report first-quarter 2024 results on May 9, before market open.Earnings Surprise HistoryIn the last reported quarter, the company’s adjusted earnings per share of $2.46 surpassed the Zacks Consensus Estimate by 2.9%. Earnings surpassed estimates in each of the trailing four quarters, the average beat being 7.07%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayThe sustained worldwide need for researc ...

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revis ...

A month has gone by since the last earnings report for Charles River Laboratories (CRL) . Shares have added about 6.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Charles River due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Charles River Q4 Earnings Beat, Mar ...

Charles River Laboratories International, Inc. (CRL) inked an AAV9 production program deal with Navega Therapeutics. The deal will grant Navega Therapeutics access to Charles River’s contract development and manufacturing capabilities and advisory services to produce the AAV gene therapy candidate NT-Z001 for phase 1 clinical trials.The recent move will bolster Charles River’s Biologics Solutions.More on the NewsUsing the accuracy of its AI-enabled zinc finger epigenome regulatory technology, Navega Therape ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z0 ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver. ...

Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.However, there are still bargains to be found… outside of the technology sector. With these three top healthcare stocks to buy, for example, there are high quality companies still selling at affordable prices. If and when the market enthusiasm spreads into the healthcare sector, these three stocks should surge.Johnson & Johnson (JNJ)Source: Alexander Tolstykh / Shutterstock.comJohns ...